Horseracing Integrity & Welfare Unit

CASE RESOLUTION WITHOUT HEARING

ADMC Program Rules 3313 & 4212/Use or Attempted Use of a Controlled Medication Substance During the Race Period
Covered Person: George Weaver
Covered Horse: Nimitz Class

On October 16, 2024, George Weaver agreed to an Admission of Equine Controlled Medication Rule Violation(s) and Acceptance of Consequences pursuant to the Anti-Doping and Medication Control (ADMC) Program in connection with the above-referenced matter. This matter involved the Use or Attempted Use of a Controlled Medication Substance during the Race Period (ADMC Program Rule 3313). On June 28, 2024, prior to Race 2 at Aqueduct Racetrack in Jamaica, New York, an employee of Mr. Weaver was observed orally administering an equine supplement product to the Covered Horse Nimitz Class. Pursuant to ADMC Program Rule 4211, and subject to the exceptions of ADMC Program Rule 4212, only feed, hay, and water are permitted during the Race Period. Accordingly, subject to the exceptions provided for in Rule 4212 (which did not apply here), any substance administered during the Race Period that does not otherwise qualify as a Banned Substance, constitutes a prohibited Controlled Medication Substance. Pursuant to ADMC Program Rule 3323(a)(3), any supplement used in contravention of Rule 4211(a) of the Prohibited List that has not been assigned a class is designated as Class C.

As a result, the following Consequences were imposed against Mr. Weaver under the ADMC Program:

1. Disqualification of the results of Nimitz Class obtained in Race 2 at Aqueduct Racetrack in Jamaica, New York on June 28, 2024, and forfeiture of all purses and other compensation, prizes, trophies, points, and rankings and repayment or surrender (as applicable) to the Race Organizer pursuant to ADMC Program Rule 3321;

2. A fine of $500 in accordance with ADMC Program Rule 3323;

3. Assignment of 1.5 Penalty Points (ADMC Program Rule 3328); and

4. Public reporting in accordance with ADMC Program Rule 3610(b) and Public Disclosure in accordance with ADMC Program Rule 3620.